文献速递眼底病与葡萄膜炎

布罗鲁珠单抗临时治疗后的短期结局:单中心经验的回顾性病例系列

SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB: A Retrospective Case Series of a Single Center Experience.
PubMed 文献 · Retina · 2022-01-01

回顾性分析51只因对贝伐珠单抗、雷珠单抗和/或阿柏西普反应不佳而换用布罗鲁珠单抗、后因眼内炎症或风险换回原抗VEGF药物的新生血管性年龄相关性黄斑变性眼。布罗鲁珠单抗 interim 治疗使41眼(41/51%,80%)解剖改善,换回原药后6个月时其中22眼(22/41%,54%)维持改善,视力无相应显著变化。

要点

  • 布罗鲁珠单抗临时治疗使41/51眼(80%)出现视网膜下液、视网膜内液或色素上皮脱离高度减少。
  • 换回原抗VEGF药后至少6个月,22/41眼(54%)维持解剖改善。
  • 治疗期间11/51眼(22%)发生眼内炎症,含1例视网膜血管炎。

核心结论

  • 布罗鲁珠单抗临时治疗使41/51眼(80%)解剖改善,换回原抗VEGF药后其中22/41眼(54%)维持至少6个月。
  • 视力无相应显著变化。

研究设计与样本

  • 回顾性病例系列,纳入51只因对贝伐珠单抗、雷珠单抗和/或阿柏西普反应不佳而换用布罗鲁珠单抗、后因眼内炎症存在或风险换回原药的新生血管性年龄相关性黄斑变性眼。
  • 在首次布罗鲁珠单抗注射(T1)、末次布罗鲁珠单抗注射(T2)及末次注射后6个月(T3)记录视力与光学相干断层扫描视网膜解剖。

主要发现

  • T2时41眼(41/51%,80%)视网膜下液减少(31眼)、视网膜内液减少(12眼)或色素上皮脱离高度减少(12眼)。
  • T3时视网膜下液减少在17眼(17/31%,55%)维持,视网膜内液减少在8眼(8/12%,67%)维持,色素上皮脱离高度减少在8眼(8/12%,67%)维持。
  • T1、T2、T3平均最小分辨角对数视力分别为0.396(约20/50)、0.441(约20/55)、0.468(约20/59)。
  • 布罗鲁珠单抗治疗期间11眼(11/51%,22%)发生眼内炎症,包括1例视网膜血管炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To examine outcomes of eyes with neovascular age-related macular degeneration that were switched to brolucizumab because of an unsatisfactory response to bevacizumab, ranibizumab, and/or aflibercept and then switched back because of the presence or risk of intraocular inflammation. METHODS: Retrospective case series of 51 eyes. Visual acuity and retinal anatomy on optical coherence tomography were recorded at the first brolucizumab injection (T1), the final brolucizumab injection (T2), and 6 months following the final brolucizumab injection (T3). RESULTS: At T2, 41 eyes (41/51%, 80%) had decreased subretinal fluid (31 eyes), intraretinal fluid (12 eyes), or pigment epithelial detachment height (12 eyes). At T3, decreased subretinal fluid was sustained in 17 eyes (17/31%, 55%), decreased intraretinal fluid was sustained in eight eyes (8/12%, 67%), and decreased pigment epithelial detachment height was sustained in eight eyes (8/12%, 67%). Mean logarithm of the minimum angle of resolution visual acuity at T1, T2, and T3 was 0.396 (∼20/50), 0.441 (∼20/55), and 0.468 (∼20/59), respectively. During the brolucizumab treatment period, 11 eyes (11/51%, 22%) developed intraocular inflammation, including one case of retinal vasculitis. CONCLUSION: Interim treatment with brolucizumab resulted in anatomical improvements in 41 eyes (41/51%, 80%) that were maintained in 22 of these eyes (22/41%, 54%) for at least 6 months after switching back to the original anti-vascular endothelial growth factor therapeutic. There were no corresponding significant changes in visual acuity.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Awh CC, Davis EC, Thomas MK, et al. SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB: A Retrospective Case Series of a Single Center Experience. Retina. 2022. PMID: 35067611. doi:10.1097/IAE.0000000000003418

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。